Use of Botulinum Toxin in Treating Rosacea: A Systematic Review

References

• Buechner SA. Rosacea: an update. Dermatology. 2005;210(2):100–108. doi:10.1159/000082564
   PubMed Web of Science ®Google Scholar
• Powell FC. Rosacea. New Engl J Med. 2005;352(8):793–803. doi:10.1056/NEJMcp042829
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Fang R, Tang K, Sun Q. The top 100 most cited articles in rosacea: a bibliometric analysis. J Eur Acad Dermatol Venereol. 2020.
   Web of Science ®Google Scholar
• Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea and its comorbidities: should be emphasized but should not be overemphasized. J Cosmet Dermatol. 2020;19(12):3414–3415. doi:10.1111/jocd.13793
   PubMed Web of Science ®Google Scholar
• Maggioni D, Cimicata A, Praticò A, et al. A preliminary clinical evaluation of a topical product for reducing slight rosacea imperfections. Clin Cosmet Investig Dermatol. 2020;13:299–308. doi:10.2147/CCID.S240784
   Web of Science ®Google Scholar
• Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587. doi:10.1067/mjd.2002.120625
   PubMed Web of Science ®Google Scholar
• Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431–438. doi:10.1111/bjd.15122
   PubMed Web of Science ®Google Scholar
• Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148–155. doi:10.1016/j.jaad.2017.08.037
   PubMed Web of Science ®Google Scholar
• Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499–512. doi:10.1016/j.jaad.2004.03.033
   PubMed Web of Science ®Google Scholar
• Abokwidir M, Feldman SR. Rosacea management. Skin Appendage Disorders. 2016;2(1–2):26–34. doi:10.1159/000446215
   PubMed Web of Science ®Google Scholar
• Berardesca E, Bonfigli A, Cribier B, et al. A split-face study assessing the clinical benefit, tolerability and subject satisfaction of a dermocosmetic in subjects with rosacea associated with erythema and sensitive skin. Clin Cosmet Investig Dermatol. 2020;13:751–758. doi:10.2147/CCID.S266879
   Web of Science ®Google Scholar
• Park JY, Ahn MK, Cho EB, Park EJ, Kim KH. Dual-frequency ultrasound as a new treatment modality for refractory rosacea: a retrospective study. Dermatol Surg. 2018;44(9):1209–1215. doi:10.1097/DSS.0000000000001552
   Web of Science ®Google Scholar
• Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O. The toxic edge-A novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med. 2019;51(4):325–331. doi:10.1002/lsm.23023
   Web of Science ®Google Scholar
• Wang Y, Zhang H, Zheng Q, Tang K, Fang R, Sun Q. Botulinum toxin as a double-edged sword in alopecia: a systematic review. J Cosmet Dermatol. 2020;19(10):2560–2565. doi:10.1111/jocd.13647
   Web of Science ®Google Scholar
• Zhang H, Tang K, Wang Y, Fang R, Sun Q. Botulinum toxin in treating Hailey-Hailey disease: a systematic review. J Cosmet Dermatol. 2021. doi:10.1111/jocd.13963
   Web of Science ®Google Scholar
• Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: updated review. J Cosmet Dermatol. 2019;18(1):10–15. doi:10.1111/jocd.12828
   PubMed Web of Science ®Google Scholar
• Alster TS, Harrison IS. Alternative Clinical Indications of Botulinum Toxin. Am J Clin Dermatol. 2020;21(6):855–880. doi:10.1007/s40257-020-00532-0
   Web of Science ®Google Scholar
• Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clin Cosmet Investig Dermatol. 2019;12:223–228. doi:10.2147/CCID.S202919
   Web of Science ®Google Scholar
• Yi DJ, Hwang S, Son J, Yushmanova I, Anson Spenta K, St Rose S. real-world safety and effectiveness of onabotulinumtoxina treatment of crow’s feet lines and glabellar lines: results of a Korean postmarketing surveillance study. Clin Cosmet Investig Dermatol. 2019;12:851–856. doi:10.2147/CCID.S227493
   Web of Science ®Google Scholar
• Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Plast Surg Nurs. 2015;35(4):184–202. doi:10.1097/PSN.0000000000000111
   Google Scholar
• Schlessinger J, Gilbert E, Cohen JL, Kaufman J. New uses of AbobotulinumtoxinA in aesthetics. Aesthet Surg J. 2017;37(suppl_1):S45–s58. doi:10.1093/asj/sjx005
   Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research Ed). 2009;339:b2535. doi:10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. doi:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716. doi:10.1046/j.1445-2197.2003.02748.x
   PubMed Web of Science ®Google Scholar
• Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic Reviews of Etiology and Risk. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017.
   Google Scholar
• Negoi I, Beuran M, Hostiuc S, Negoi RI, Inoue Y. Surgical anatomy of the superior mesenteric vessels related to colon and pancreatic surgery: a systematic review and meta-analysis. Sci Rep. 2018;8(1):4184. doi:10.1038/s41598-018-22641-x
   Web of Science ®Google Scholar
• Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. Journal of Drugs in dermatology: JDD. 2012;11(12):e76–79.
   Google Scholar
• Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015;41(Suppl 1):S9–16. doi:10.1097/DSS.0000000000000277
   Web of Science ®Google Scholar
• Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology (Basel, Switzerland). 2015;230(4):299–301. doi:10.1159/000368773
   Web of Science ®Google Scholar
• Dayan SH, Ashourian N, Cho K, Pilot A. Double-blind, placebo-controlled study to assess the efficacy and safety of IncobotulinumtoxinA injections in the treatment of Rosacea. Journal of Drugs in Dermatology: JDD. 2017;16(6):549–554.
   Web of Science ®Google Scholar
• Park KY, Kwon HJ, Kim JM, et al. A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic Rosacea. Ann Dermatol. 2018;30(6):688. doi:10.5021/ad.2018.30.6.688
   Web of Science ®Google Scholar
• Bharti J, Sonthalia S, Jakhar D. Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. J Am Acad Dermatol. 2018. doi:10.1016/j.jaad.2018.05.014
   Google Scholar
• Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in Rosacea patients with facial erythema. Dermatol Surg. 2019;45(9):1155–1162. doi:10.1097/DSS.0000000000001819
   Web of Science ®Google Scholar
• Al-Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020;33(6):e13976. doi:10.1111/dth.13976
   PubMed Web of Science ®Google Scholar
• Dayan SH, Ashourian N, Cho K, Pilot A. Double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea. J Drugs Dermatol. 2017;16(6):549–554.
   Web of Science ®Google Scholar
• Engin B, Özkoca D, Kutlubay Z, Serdaroğlu S. Conventional and novel treatment modalities in Rosacea. Clin Cosmet Investig Dermatol. 2020;13:179–186. doi:10.2147/CCID.S194074
   PubMed Web of Science ®Google Scholar
• Dursun R, Daye M, Durmaz K. Acne and rosacea: what’s new for treatment? Dermatol Ther. 2019;32(5):e13020. doi:10.1111/dth.13020
   Web of Science ®Google Scholar
• Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea treatment: review and update. Dermatol Ther (Heidelb). 2021;11(1):13–24. doi:10.1007/s13555-020-00461-0
   PubMed Web of Science ®Google Scholar
• Juliandri J, Wang X, Liu Z, Zhang J, Xu Y, Yuan C. Global rosacea treatment guidelines and expert consensus points: the differences. J Cosmet Dermatol. 2019;18(4):960–965. doi:10.1111/jocd.12903
   PubMed Web of Science ®Google Scholar
• Gold MH, Lebwohl M, Biesman BS, et al. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment. J Am Acad Dermatol. 2018;79(3):e57–e59. doi:10.1016/j.jaad.2018.05.037
   PubMed Web of Science ®Google Scholar
• Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907–912. doi:10.1016/j.jaad.2004.01.048
   PubMed Web of Science ®Google Scholar
• Roh NK, Kim MJ, Lee YW, Choe YB, Ahn KJ. A split-face study of the effects of a stabilized hyaluronic acid-based gel of nonanimal origin for facial skin rejuvenation using a stamp-type multineedle injector: a randomized clinical trial. Plast Reconstr Surg. 2016;137(3):809–816. doi:10.1097/01.prs.0000480686.68275.60
   PubMed Web of Science ®Google Scholar
• Heatherton TF, Development PJ. Validation of a Scale for Measuring State Self-Esteem. J Pers Soc Psychol. 1991;60(6):895–910. doi:10.1037/0022-3514.60.6.895
   Web of Science ®Google Scholar
• Fukui T, Rahman M, Sekimoto M, et al. Study design, statistical method, and level of evidence in Japanese and American clinical journals. J Epidemiol. 2002;12(3):266–270. doi:10.2188/jea.12.266
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane. 2019.
   Google Scholar
• Saffarian P, Fooladi AAI. Topical botulinum toxin: a non-invasive way for treatment of muscle disorders. Curr Drug Deliv. 2018;15(10):1375–1380. doi:10.2174/1567201815666180730140704
   Web of Science ®Google Scholar
• Collins A, Nasir A. Topical botulinum toxin. J Clin Aesthet Dermatol. 2010;3(3):35–39.
   Google Scholar
• Lueangarun S, Sermsilp C, Tempark T. Topical Botulinum Toxin Type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(8):1094–1101. doi:10.1097/DSS.0000000000001532
   PubMed Web of Science ®Google Scholar
• Chajchir I, Modi P, Chajchir A. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck. Aesthetic Plast Surg. 2008;32(5):715–722; discussion 723. doi:10.1007/s00266-008-9151-9
   Web of Science ®Google Scholar
• Glogau R, Blitzer A, Brandt F, Kane M, Monheit GD, Waugh JM. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. Journal of Drugs in Dermatology: JDD. 2012;11(1):38–45.
   Web of Science ®Google Scholar
• Issa MC, Torreao PS, Boechat M, Luiz R. Early investigations in drug delivery of onabotulinum toxin A using combined fractional ablative laser with impact ultrasound vs. injections of onabotulinum toxin A for palmar hyperhidrosis: a right-left comparison trial. Br J Dermatol. 2018;179(5):1168–1169. doi:10.1111/bjd.16781
   PubMed Web of Science ®Google Scholar
• Zhu J, Ji X, Li M, et al. The efficacy and safety of fractional CO2 laser combined with topical Type A botulinum toxin for facial rejuvenation: a randomized controlled split-face study. Biomed Res Int. 2016;2016:3853754. doi:10.1155/2016/3853754
   Web of Science ®Google Scholar
• Schilling LM, Halvorson CR, Weiss RA, Weiss MA, Beasley KL. Safety of combination laser or intense pulsed light therapies and doxycycline for the treatment of Rosacea. Dermatol Surg. 2019;45(11):1401–1405. doi:10.1097/DSS.0000000000002009
   Web of Science ®Google Scholar
• Ebneyamin E, Mansouri P, Rajabi M, Qomi M, Asgharian R, Azizian Z. The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: a double-blind, controlled clinical trial. J Cosmet Dermatol. 2019;19(6):1426–1431. doi:10.1111/jocd.13177
   Web of Science ®Google Scholar
• Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58–64. doi:10.1016/j.jdermsci.2018.12.004
   Web of Science ®Google Scholar